# A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat

Source: https://onco.cc/trials/nct06508216/  
OnCo record `nct06508216` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of datopotamab deruxtecan and durvalumab in triple-negative breast cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.

## Summary

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer is a phase 1/2, randomised interventional study registered as NCT06508216 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 50 participants, started 2024-07-05 and due to reach its primary completion in 2025-12-17. Interventions recorded: Dato-DXd; Durvalumab. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "Patients who have early relapsed triple negative breast cancer i". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: COMPASS-TNBC
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06508216
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06508216: https://clinicaltrials.gov/study/NCT06508216

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06508216.json